Not all astrocyte lipid droplets are created equal. In the August 19 Nature Communications, scientists led by Priyanka Narayan at the National Institutes of Health in Bethesda, Maryland, report that ...
Most of the known genetic risk for Alzheimer’s disease is explained by single-letter DNA changes found in genome-wide association studies. Large structural rearrangements, such as copy-number variants ...
The FDA has given the nod to two blood tests for Alzheimer’s disease. On August 20 they cleared C2N’s Precivity AD2 test. On August 24, they announced that Roche’s Elecsys p-tau217 passed muster. Both ...
Microglia in human brain are descended from progenitor cells that arose in the embryonic yolk sac—but does this remain the case life-long? Two new papers argue that in late adulthood, these original ...
Scientists have tried several ways to restrain tau pathology, with varied success. Here’s a new one: alter splicing of the tau gene, MAPT, so that neurons make less of the aggregation-prone 4R isoform ...
ALSP, Inc. is developing a small molecule drug for Alzheimer's Disease. As an employee of this company, I have a financial interest in the success of it's drug.
Brian Austen, MA; PhD St George's Hospital Medical School Contact Information Brian Austen, MA; PhD LONDON SW17 ORE ...
Contact Information Leonora Grant, J.D. Avondale Estates, United States Professional Information --None-- ...
Contact Information Hangyu Wu Gungzhou, China Professional Information ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...